Two new study sites are now enrolling for our MDMA-assisted therapy for PTSD Expanded Access program. The Pearl Institute in Waynesville, North Carolina, and Sage Integrative Health in Berkeley, California, …
Our Expanded Access Program study site at Sage Integrative Health in Berkeley, California, began screening participants for MDMA-assisted therapy for PTSD in early March. Our multi-site expanded access …
Our multi-site expanded access study site for MDMA-assisted therapy for patients with treatment-resistant PTSD at the Pearl Psychedelic Institute in Waynesville, North Carolina, was activated for phone …
On December 10, 2021, our multi-site expanded access study site for MDMA-assisted therapy for patients with treatment-resistant PTSD at the Pearl Psychedelic Institute in Waynesville, North Carolina, was …
On December 20, 2019, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on MAPS’ proposed Expanded Access protocol for MDMA-assisted psychotherapy for posttraumatic stress disorder …
On October 15, 2019, the U.S. Food and Drug Administration (FDA) responded to MAPS with a continued clinical hold with safety concerns regarding the submitted protocol for an Expanded Access program for …
On September 15, 2019, MAPS responded to the U.S. Food and Drug Administration’s (FDA) continued clinical hold with Protocol A3V1 and agreed to all.
On July 12, 2019, MAPS received a response from the U.S. Food and Drug Administration (FDA) regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic …
In June 2019, MAPS responded to the U.S. Food and Drug Administration’s (FDA) continue clinical hold letter regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy …
In May 2019, the U.S. Food and Drug Administration (FDA) sent a formal response to MAPS regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic …
In April 2019, MAPS Public Benefit Corporation (MAPS PBC) sent a response to the clinical hold letter received by the U.S. Food and Drug Administration (FDA) regarding the submitted protocol for an Expanded …
In March 2019, MAPS Public Benefit Corporation (MAPS PBC) received a clinical hold letter from the U.S. Food and Drug Administration (FDA) regarding the submitted protocol for an Expanded Access program …
